Conformal Therapy for Lung Cancer

advertisement

Conformal Therapy for Lung Cancer

B. Schicker, F.J. Schwab*, U. Götz

Institute of Radiotherapy and Radiation Oncology

St. Vincenz-Krankenhaus Limburg

*Clinic of Radiotherapy

University of Würzburg

Definition

INTRODUCTION

For lung cancer radiotherapy is an essential treatment mode.

The major problem for the treatment planning is the fact that the target volume is surrounded by organs at risk. Acute or late reactions of the lung, the myelon and the heart are dose limiting factors. If curative doses are aspired the old fashioned opposed fields techniques are not applicable because of the high dose load to the organs at risk. Curative doses for lung cancer, however, usually exceed 70 Gy. Therefore conformal treatment techniques have to be developed aiming at the reduction of the normal tissue complication probability and the high tumor control probability.

ADJUVANT TREATMENT

For local advanced tumor stages the postoperative irradiation of the regional lymphatics and of the bronchial stump is indicated.

The mediastinum should always be included in the clinical target volume if involved nodes were found but no systematic lymph node dissection was performed. The supraclavicular lymph nodes are not included in the CTV for adjuvant treatment with curative intent. The involvement of these lymph nodes probably improves local control, whereas the improvement of survival remains questionable. The lymph nodes included in the CTV are: the intrapulmonary, the subcarinal, the tracheobronchial, the paratracheal and the preaortic group. For lower lobe primaries the inclusion of the lymph nodes along the ligamentum pulmonale and the paraesophageal nodes should be considered.

Radiotherapy

decades ago

Conventional Opposed Fields Technique based on radiographs

Conventional Opposed Fields Technique

Change from Radiograph to Target Volume

Traditional irradiation portals recommended in textbooks for irradiation of lung cancer patients.

selected clinical target volume based on the oncological principles (no inclusion of the supraclavicular and contralateral hilar lymph nodes in the CTV for curative RT).

Development of Conformal Treatment

Techniques

 first step: precise definiton of the planning target volume based on oncological criteria

 conformal treatment = precise irradiation of a precisely defined PTV

Z +8

Z -2

Target Volume for adjuvant treatment

Z +3 Z +0

Z -4 Z -8

Definition

CONFORMAL RADIOTHRAPY

A high dose to the PTV means a high tumour control probability were as a low dose to the normal tissue or organ at risk means a low normal tissue complication probability

Low side effects = live quality for the Patient

BENEFIT FOR PATIENT

Ideal Treatment vs. Reality

Dose Distribution

Ideal:

D(PTV) = 100%

D(NT,OAR) = 0%

Real:

D(PTV) ~ 100%

D(NT,OAR) >> 0%

Ideal Treatment vs. Reality

Dose Volume Histogram

100

Volume [%] Volume [%]

100

Normal Tissue,

Organ at Risk

PTV

100

Dose [%]

100

Dose [%]

Aim of the Optimization

- minimum requirements -

High TCP and low NTCP: high dose within the PTV and a good protection of the

OAR

Reduction of the dose to the OAR below critical values

(tolerance doses)

Concentration of the therapeutic dose on the PTV:

Dose homogeneity within the PTV

(ICRU recommendations -5 % ... +7 %)

Development of a 3-D Conformal Standard

Technique for Lung Cancer

From opposed fields to conformal technique

=>

???

Definition

3 Dimensional Conformal

- CT based Treatment planning

- Slice distance 1.0 or 0.5 cm

- Definition and delineation of PTV and Organ at risk in every slice

- using other imaging procedures as MR, PET etc.

-Calculation and optimisation of the dose distribution in every CT slice to achieve a homogenous dose distribution

Development of a

Standard Technique for

Lung Cancer

PTV

Lung

Heart

Myelon

Development of a

Standard Technique for

Lung Cancer

PTV

Lung

Heart

Myelon

Development of a

Standard Technique for

Lung Cancer

PTV

Lung

Heart

Myelon

Development of a

Standard Technique for

Lung Cancer

PTV

Lung

Heart

Myelon

Development of a

Standard Technique for

Lung Cancer

PTV

Lung

Heart

Myelon

Development of a

Standard Technique for

Lung Cancer

PTV

Lung

Heart

Myelon

Development of a

Standard Technique for

Lung Cancer

PTV

Lung

Heart

Myelon

Development of a Standard Technique

Standard Beam Set up

- Isocenter – placed at the ventral tip of the vertebral body

- easy to find uneder X-Ray controll from 0° and also 90° gantry angle

Development of a Standard Technique

Standard Beam Set up

Aim of Field 1 is to spare a maximum volume of both lungs

F1

Development of a Standard Technique

Standard Beam Set up

The gantry angle and blocking of field 2 (135°) was chosen to protect the myelon

F2

135°

Development of a Standard Technique

Standard Beam Set up

Field 3 (40°) reduce the high dose regions in the left lung and contribute to a better adaptation of the isodoses to the PTV

Standard Technique at the ISRO Limburg

3 fields: 0° fixed wedge (lung)

~ 140° fixed wedge (myelon)

40° ... 80° fixed or arc, wedge ?

myelon)

(heart, contralateral lung, start with dose contribution 1 : 1 : 1 field shaping using beams eye view

 good protection of the contra-lateral lung myelon dose (adjustable from 30% to 70%) below critical values for curative total doses

Clinical Case 1

Adjuvant Treatment

The 72 year old patient with a non small cell left localized lung cancer was operated. The primary lung cancer infiltrated the left pulmonary artery.

A questionable R0 resection was performed. An adjuvant radiotherapy was indicated. From 12 examined lymph nodes 5 were found involved. A total dose of 66.6 Gy was applied in this clinical case. For the main series the target volume was treated with a dose of 50.4 Gy and for the boost technique a dose of 16.2 Gy was given. For both series a dose per fraction of 1.8 Gy was chosen.

ZV

+4 cm

ZV

-1 cm

ZV

-3 cm

Clinical Case 1

Clinical Case 1

Field 3 (35°) and

4 (100°) reduce the high dose regions in the left lung and contribute a better adaption of the isodoses to the PTV.

Clinical Case 1

Full homogeneity over all slices requires two further fields (5 and 6).

Conformal Therapy for Lung Cancer

First International

Symposium on

Target Volume

Definition

F.Schwab

Technique for Case 1

Variation of the Standard Technique

95%

85%

70%

50%

HS

+6 cm

Clinical Case 1

95%

85%

70%

50%

HS

+4 cm

95%

85%

70%

50%

HS

0 cm

95%

85%

70%

50%

Clinical Case 1 HS

-1 cm

Clinical Case 1

95%

85%

70%

50%

HS

-3 cm

95%

85%

70%

50%

HS

- 4 cm

Clinical Case 1 frontal / sagittal dose distribution frontal sagittal

100%

95%

90%

85%

80%

70%

50%

30%

10%

Clinical Case 1

DVH

PTV

Myelon

Lung

Clinical Case 1

DVH Box / 3 Field Technique

Myelon

Lung

PTV

Clinical Case 1

Boost

Clinical Case 1

Boost – Beam Setup

95%

85%

70%

50%

BST

-1 cm

Clinical Case 2

Radiotherapy after Pneumonectomy

A 46 year old male patient with a left located non small cell lung cancer of the upper lobe with infiltration of the upper lung vein. Nine involved nodes from 29 examined nodes were described. In many of the examined lymph nodes a capsule disruption was found. The CTV includes the paratracheal area, the upper mediastinum, the aortic pulmonary window, the left hilus and the subcarinal area. The lymph node capsule disruption and the infiltration of the upper pulmonary vein determine the necessity of a high total dose (at least 66 Gy).

Clinical Case 2

Clinical Case 2

+ 8 cm

100%

95%

90%

85%

80%

70%

50%

30%

10%

Clinical Case 2

+6 cm

100%

95%

90%

85%

80%

70%

50%

30%

10%

Clinical Case 2

- 2 cm

100%

95%

90%

85%

80%

70%

50%

30%

10%

Clinical Case 2

Myelon

Lung

PTV

100%

95%

90%

85%

80%

70%

50%

30%

10%

Clinical Case 3

Definitive radiotherapy

A primary inoperable periphery non-small cell lung cancer of the right upper lobe was diagnosed for the

77 year old female patient. In this case the CTV included only the tumor with small margins as shown in figure 23A and B. A total dose of 68.4 Gy was applied.

Clinical Case 3

Clinical Case 3

95%

85%

70%

50%

Clinical Case 3

95%

85%

70%

50%

Evaluation of the Treatment Plans

 do the isodoses only look nice or can the patient profit from the conformal technique?

=> analysis of the DVHs

Treatment Index TI

TI := QI(PTV)/(Dmax(m)*QI(m)+Dmean(l)*QI(l)+Dmean(h)*QI(h)) m = myelon l = lung (left and right) h = heart / myocard side condition: no violation of critical doses

Evaluation of the Treatment Plans

Treatment Index

Treatment Index TI

3,50

3,00

2,50

2,00

1,50

1,00

0,50

0,00

1,40 a)

1,56

1,90

2,65

3,00

3,09

270)

Box

- 4F

Star 3F

Standard 6F case

Technique

1

TI=QI(PTV)/(Dmax(m)*QI(m)+Dmean(l)*QI(l)+Dmean(h)*QI(h))

Conclusions and Discussion

The prerequisite for a conformal therapy is a precisely defined target volume in a 3D patient model. The target volume has to be defined on the basis of oncological criteria and the success of the therapy has to be checked in clinical studies. The clinical target volumes presented here for the adjuvant and definitive radiotherapy are different from that nowadays usually shown in the clinical textbooks.

Conclusions and Discussion

One of the advantages of conformal treatment planning is the reduction of the dose load to the normal tissue and to the organs at risk compared to an opposite field technique. The dose at the organs at risk is lowered in two ways: First the total dose is reduced on the basis of the conformal treatment and second the dose per fraction is reduced resulting in a lowering of the biological effective dose at the organs at risk. Both effects in combination allow the application of curative doses to the target volume. The conformal techniques, however, also require an improvement in patient positioning. Finally, modern techniques like intensity modulated therapy may in future help to improve the homogeneity of the dose distribution.

Conclusion and Future

 conformal therapy => improvement of the treatment quality

 conformal therapy => reduction of the high dose region for the OARs (responsible for side-effects)

 lowering of the daily dose to the OAR additionally reduces the biological effective dose

IMRT for enhanced dose homogeneity

 optimized depth doses (proton facilities)

Download